DBP International AB: Full approval for SI-053 from The Ethics Commission of the Faculty of Medicine of Cologne University in Germany has been received
Double Bond Pharmaceutical International AB (publ) ("DBP") is very delighted to announce that the company has received for its product SI-053 full approval for starting clinical trials in Germany, in patients with glioblastoma.Up to now, the SI-053 has obtained all approvals from the countries (Germany and the Netherlands) where the clinical trial is to be conducted. "We are very excited to reach this crucial milestone. It is a result of lots of hard work done by our excellent colleagues, our preclinical and clinical partners, external consultants and KOLs, and all our investors who have